Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, #99 Huaihai Xi Road, Jiangsu, 221002, Xuzhou, China.
Langenbecks Arch Surg. 2022 Nov;407(7):2789-2799. doi: 10.1007/s00423-022-02478-9. Epub 2022 May 30.
Recently, the efficacy and outcomes of total laparoscopic pancreaticoduodenectomy (TLPD) have been well established; however, specific data regarding the clinical outcomes of total laparoscopic versus open pancreaticoduodenectomy (OPD) are still limited. The present study aims to directly compare the clinical and oncological outcomes following TLPD versus OPD at a single institution.
The clinical data of 127 consecutive patients who underwent TLPD (n = 69) and OPD (n = 58) and were admitted to our department between January 2017 and June 2019 were analysed retrospectively. The short-term and oncological outcomes in the two groups were compared.
Compared to the OPD group, the TLPD group experienced a longer operative time [(399.1 ± 77.9) min vs. (247.9 ± 61.8) min] and significantly earlier oral intake [5.0 (IQR, 4.0-6.0) days vs. 8.0 (IQR, 6.0-8.0) days], earlier postoperative exhaust [3.0 (IQR, 3.0-4.0) days vs. 4.0 (IQR, 4.0-4.5) days], earlier out-of-bed activity [2.0 (IQR, 1.0-2.3) days vs. 3.0 (IQR, 2.0-3.0) days], earlier nasogastric tube removal [5.5 (IQR, 4.0-7.8) days vs. 8.0 (IQR, 6.0-11.0) days] and shorter postoperative length of hospital stay [14.0 (IQR, 11.0-21.0) days vs. 16.0 (IQR, 12.0-25.0) days] (P < 0.05). The estimated blood loss [(334.4 ± 157.8) mL vs. (344.6 ± 259.1) mL], presence of clinically relevant postoperative pancreatic fistula (grade B/C, 5.8% vs. 5.2%) and the overall complication rate (23.2% vs. 25.9%) did not significantly differ between the two groups (P > 0.05). Regarding the oncological outcomes, there were no significant differences in pathological types, tumour size, lymph nodes harvested, tumour stages or resection margins, or in overall survival (OS) (56.9% vs. 53.2%, P = 0.704) or progression-free survival (PFS) (48.3% vs. 46.8%, P = 0.881) with a median 26-month follow-up.
TLPD is a safe and feasible procedure in select patients after a certain learning curve. Compared with OPD, TLPD has equivalent short-term and oncological outcomes and offers the advantages of faster postoperative recovery and shorter length of hospital stay.
全腹腔镜胰十二指肠切除术(TLPD)的疗效和结果已得到充分证实;然而,关于 TLPD 与开腹胰十二指肠切除术(OPD)的临床结果的具体数据仍然有限。本研究旨在在一家医院内直接比较 TLPD 与 OPD 的临床和肿瘤学结果。
回顾性分析了 2017 年 1 月至 2019 年 6 月期间在我院接受 TLPD(n=69)和 OPD(n=58)治疗的 127 例连续患者的临床数据。比较了两组患者的短期和肿瘤学结局。
与 OPD 组相比,TLPD 组手术时间更长[(399.1±77.9)min vs. (247.9±61.8)min],术后首次口服时间更早[5.0(IQR,4.0-6.0)天 vs. 8.0(IQR,6.0-8.0)天],术后首次排气时间更早[3.0(IQR,3.0-4.0)天 vs. 4.0(IQR,4.0-4.5)天],术后首次下床活动时间更早[2.0(IQR,1.0-2.3)天 vs. 3.0(IQR,2.0-3.0)天],术后首次拔除胃管时间更早[5.5(IQR,4.0-7.8)天 vs. 8.0(IQR,6.0-11.0)天],术后住院时间更短[14.0(IQR,11.0-21.0)天 vs. 16.0(IQR,12.0-25.0)天](P<0.05)。两组估计出血量[(334.4±157.8)mL vs. (344.6±259.1)mL]、术后临床相关胰瘘(B/C 级,5.8% vs. 5.2%)发生率和总并发症发生率(23.2% vs. 25.9%)差异均无统计学意义(P>0.05)。在肿瘤学结果方面,两组患者的病理类型、肿瘤大小、淋巴结清扫数目、肿瘤分期和切除边缘以及总生存率(OS)(56.9% vs. 53.2%,P=0.704)或无进展生存率(PFS)(48.3% vs. 46.8%,P=0.881)无显著差异,中位随访 26 个月。
TLPD 是一种安全可行的方法,在一定的学习曲线后适用于选择的患者。与 OPD 相比,TLPD 具有同等的短期和肿瘤学结果,并具有更快的术后恢复和更短的住院时间的优势。